Cytochrome P450 2D6 genotype variation and venlafaxine dosage.

doi:10.4065/82.9.1065

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Cytochrome P450 2D6 genotype variation and venlafaxine dosage.

Mayo Clinic proceedings - 1 Sept 2007

McAlpine Donald E, O'Kane Dennis J, Black John L, Mrazek David A

Abstract excerpt

OBJECTIVE: To determine whether the presence or absence of a fully functioning cytochrome P450 2D6 allele was associated with the dosage of the antidepressant drug venlafaxine in patients who had either adverse effects or absence of a therapeutic response to treatment with the immediate release or extended release form of venlafaxine. PATIENTS AND METHODS: We reviewed the electronic medical records of 199...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents, Second-Generation
Share to Anxiety Disorders
Share to Cyclohexanols
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Delayed-Action Preparations

Share to Depressive Disorder, Major

Share to Treatment Failure

Share to Venlafaxine Hydrochloride

Source

Open in PubMed

Identifiers

PMID: 17803873
DOI: 10.4065/82.9.1065

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.